Strategic Entry into China’s Rare Disease Market
A structured approach for international pharmaceutical and biotech companies navigating China’s rare disease regulatory, access, and ecosystem complexity.China’s rare disease market is entering a critical transformation phase. Regulatory acceleration, the establishment of the Rare Disease List (RDL), advances in genetic testing, and evolving reimbursement mechanisms have created new opportunities for innovative therapies.
At the same time, China remains one of the most complex and high-risk environments for rare disease market entry, where regulatory sequencing, pricing misalignment, and premature partnerships can irreversibly compromise long-term value.
Understanding China’s Rare Disease Market
China is home to an estimated 20 million patients affected by rare diseases, yet historically access to diagnosis and treatment has been limited. Over the past decade, rare diseases have become a national healthcare priority, driven by policy reforms aimed at improving patient outcomes and accelerating access to innovative therapies.
The creation of the Rare Disease List (RDL) has reshaped China’s regulatory landscape, enabling priority review pathways for qualifying treatments and signaling strong government commitment to orphan drug development. Parallel to this, rapid progress in genetic testing — particularly Next Generation Sequencing (NGS) — has significantly improved diagnostic capabilities, directly influencing treatment adoption and patient identification.
Despite these advances, market entry remains complex. Regulatory approval does not guarantee access, reimbursement pathways are fragmented across national and regional levels, and healthcare infrastructure varies significantly between major urban centers and lower-tier regions. Success in China’s rare disease market requires coordinated regulatory, market access, pricing, and ecosystem strategies — executed in the correct sequence.
Why Rare Disease Market Entry Fails in China
Assuming Rare Disease List inclusion guarantees pricing or reimbursement
Misalignment between regulatory approval and diagnostic readiness
Underestimating the role of genetic testing access in patient identification
Entering licensing or distribution agreements too early
In rare disease, early missteps often lock companies into suboptimal regulatory or commercial pathways for years.
Our Role in the Rare Disease Market
JUMO Partners serves as a trusted China authority and operating partner for European pharmaceutical and biotech companies addressing rare diseases. Our role is to reduce strategic, regulatory, and personal risk for decision-makers operating in a highly complex healthcare environment characterized by evolving regulations, fragmented patient pathways, and limited epidemiological visibility.
Unlike traditional advisors focused on high-level analysis, we assume responsibility for informed execution. We combine regulatory expertise, medical-scientific understanding, and on-the-ground engagement to anchor rare disease strategies in regulatory feasibility, institutional dynamics, and real-world patient pathways.
-
- Validation of China rare disease opportunity through real-world epidemiology and unmet-need assessment
- Design of NMPA registration and access strategies aligned with clinical development stage
- Mapping and qualification of key hospitals, reference centers, and investigators
- Engagement with clinicians, KOLs, and patient organizations
- Assessment of pricing, reimbursement, and access scenarios under evolving NRDL frameworks
- Structured pilot initiatives supporting evidence-based scale-up or strategic exit
Discuss Your China Rare Disease Strategy
Entering China’s rare disease market is a CEO- and Board-level decision involving regulatory exposure, pricing constraints, and long-term access implications. A focused discussion helps clarify feasibility, risk, and strategic sequencing before irreversible commitments are made.
Download the White Paper
Strategic Entry into China’s Rare Disease Market
A practical guide for international pharmaceutical and biotech companies covering regulatory pathways, genetic testing dynamics, pricing and reimbursement frameworks, digital health platforms, and go-to-market strategies tailored to China’s rare disease ecosystem.
